HC Wainwright set a $22.00 price target on Iovance Biotherapeutics (NASDAQ:IOVA) in a research report released on Tuesday. The brokerage currently has a buy rating on the biotechnology company’s stock.

Several other brokerages have also recently issued reports on IOVA. BidaskClub raised shares of Iovance Biotherapeutics from a hold rating to a buy rating in a research note on Saturday, May 19th. B. Riley upped their price objective on shares of Iovance Biotherapeutics from $22.00 to $24.00 and gave the company a buy rating in a research note on Friday, May 11th. ValuEngine raised shares of Iovance Biotherapeutics from a buy rating to a strong-buy rating in a research note on Wednesday, May 2nd. Zacks Investment Research cut shares of Iovance Biotherapeutics from a buy rating to a hold rating in a research note on Wednesday, July 18th. Finally, Chardan Capital reaffirmed a buy rating and set a $30.00 price objective on shares of Iovance Biotherapeutics in a research note on Friday, July 6th. Two equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus price target of $22.69.

Iovance Biotherapeutics traded down $0.55, hitting $14.15, during trading hours on Tuesday, according to Marketbeat Ratings. 8,457 shares of the company’s stock traded hands, compared to its average volume of 677,303. Iovance Biotherapeutics has a 52-week low of $4.45 and a 52-week high of $19.90. The stock has a market cap of $1.23 billion, a PE ratio of -10.50 and a beta of 2.72.

Iovance Biotherapeutics (NASDAQ:IOVA) last announced its quarterly earnings data on Monday, August 6th. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.02). research analysts anticipate that Iovance Biotherapeutics will post -1.26 earnings per share for the current fiscal year.

Institutional investors have recently bought and sold shares of the company. Quantbot Technologies LP purchased a new stake in shares of Iovance Biotherapeutics in the 1st quarter valued at approximately $100,000. Fred Alger Management Inc. purchased a new stake in shares of Iovance Biotherapeutics in the 2nd quarter valued at approximately $102,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Iovance Biotherapeutics in the 1st quarter valued at approximately $145,000. Trexquant Investment LP purchased a new stake in shares of Iovance Biotherapeutics in the 2nd quarter valued at approximately $129,000. Finally, Xact Kapitalforvaltning AB purchased a new stake in shares of Iovance Biotherapeutics in the 1st quarter valued at approximately $174,000. 86.53% of the stock is owned by institutional investors and hedge funds.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is LN-144, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of metastatic melanoma.

Featured Story: Trading Strategy Methods and Types

Analyst Recommendations for Iovance Biotherapeutics (NASDAQ:IOVA)

Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.